Inactive

REQUEST FOR INFORMATION **** Email address corrected as follows: usarmy.detrick.dod-jpeo-cbrnd.mbx.mcs-rfi@mail.mil **** U.S. Ambulatory Outpatient Trial of Humira® (Adalimumab) in COVID-19 ****Full A... REQUEST FOR INFORMATION **** Email address corrected as follows: usarmy.detrick.dod-jpeo-cbrnd.mbx.mcs-rfi@mail.mil **** U.S. Ambulatory Outpatient Trial of Humira® (Adalimumab) in COVID-19 ****Full Announcement Attached to this Posting**** Objective: This is a Request for Information (RFI) for planning purposes only. It is not to be construed as a commitment by the Government nor will the Government pay for the information solicited. No solicitation document exists or is guaranteed to be issued as a result of this RFI. The Joint Program Executive Office for Chemical and Biological Defense (Medical Countermeasures Systems) is seeking information on the capabilities and willingness of private entities (academic, non-profit and commercial) in the areas listed below.